BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 02, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/30 cls
Active Biotech AB (SSE:ACTI) Jefferies Peter Welford Upgrade Hold (from underperform) 0% SEK46.60
Welford also raised his target to CHF40 from CHF14. He noted that discussions with partner Ipsen Group (Euronext:IPN) regarding tasquinimod (TASQ) "suggest encouraging enrollment in the Phase III first-line metastatic castration-resistant prostate cancer (CRPC) trial, and mid-term plans to expand development if this study demonstrates a PFS benefit." Active Biotech is partnered with Ipsen to co-develop and commercialize Active Biotech's TASQ, a second-generation linomide. Welford also says the company has funds to carry it well into 2H13.
Affymax Inc. (NASDAQ:AFFY) Baird Christopher Raymond Price target Market outperform -13% $11.74
Rodman Michael King Price target Market outperform
Raymond raised his target to $17 from $15 after FDA...

Read the full 951 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >